Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine-sEEG
NCT07768618Phase 2Not yet recruiting
- Sponsor
- Emory University
- Start
- Dec 2026
- Primary completion
- Dec 2031
- Countries
- 1
01
Overview
A Phase 2 trial of ketamine in major depressive disorder (MDD), sponsored by Emory University. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07768618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07768618.